Skyepharma Plc (SKYEY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 146,626 | 121,620 | 97,950 | 79,090 | 0 |
| Cost of Goods | 65,898 | 54,220 | 51,950 | 33,120 | N/A |
| Gross Profit | 80,729 | 67,400 | 46,000 | 45,960 | N/A |
| Operating Expenses | 33,464 | 30,310 | 25,330 | 27,080 | 0 |
| Operating Income | 48,162 | 37,090 | 20,670 | 18,890 | N/A |
| Interest Expense | 1,988 | 11,530 | 22,060 | 18,700 | 0 |
| Other Income | 459 | -41,870 | -170 | -16,670 | 0 |
| Pre-tax Income | 46,633 | -16,310 | -1,560 | -16,480 | 0 |
| Income Tax | 6,422 | 980 | -2,810 | 310 | N/A |
| Net Income Continuous | 40,211 | -17,303 | 1,252 | 507 | N/A |
| Net Income Discontinuous | N/A | 0 | 0 | 9,820 | N/A |
| Net Income | $40,211 | $-17,300 | $1,250 | $-6,970 | $N/A |
| EPS Basic Total Ops | 0.38 | -0.20 | 0.03 | -0.24 | N/A |
| EPS Basic Continuous Ops | 0.38 | -0.20 | 0.03 | 0.02 | N/A |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | 0.33 | N/A |
| EPS Diluted Total Ops | 0.38 | -0.20 | 0.03 | -0.24 | N/A |
| EPS Diluted Continuous Ops | 0.38 | -0.20 | 0.03 | 0.02 | N/A |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 0.33 | N/A |
| EPS Diluted Before Non-Recurring Items | 0.38 | N/A | N/A | N/A | 0.03 |
| EBITDA(a) | $52,443 | $42,360 | $27,390 | $23,640 | $N/A |